Cited by 227SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral Infections and Outbreaks Research

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Open access

Choe, Pyoeng Gyun, Perera, R.A.P.M., Park, Wan Beom, Song, Kyoung-Ho, Bang, Ji Hwan, Kim, Eu Suk, Kim, Hong Bin, Ko, Long Wei Ronald, Park, Sang Won, Kim, Nam-Joong, Lau, Eric H.Y., Poon, Leo L.M., Peiris, Malik, Oh, Myoung-don·2017·Emerging Infectious Diseases

DOI 10.3201/eid2307.170310PMC PMC5512479

Open this paper in CoChat — free account Open PDF

Abstract

We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3201/eid2307.170310

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P. R., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K., Convalescent Plasma Study Group, Nguyen‐Van‐Tam, J. S., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 985
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection
Corman, V. M., Albarrak, A. M., Omrani, A. S., Albarrak, M. M., Farah, M. E., Almasri, M. M., Muth, D., Sieberg, A., Meyer, B., Assiri, A. M., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ951 · Cited by 370
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013
Perera, R. A. P. M., Wang, P., Gomaa, M. R., El‐Shesheny, R., Kandeil, A., Bagato, O., Siu, L. Y.-L., Shehata, M., Kayed, A. E., Moatasim, Y., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.36.20574 · Cited by 323
Self-citation
Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015
Prevention, K. C. F. D. C. A. (2015) · Osong Public Health and Research Perspectives · doi:10.1016/j.phrp.2015.08.006 · Cited by 262
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Arabi, Y. M., Hajeer, A. H., Luke, T. C., Raviprakash, K. S., Balkhy, H. H., Johani, S. A., Al‐Dawood, A., Al-Qahtani, S. M., Al‐Omari, A., Al-Hameed, F. M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2209.151164 · Cited by 248
Viral Load Kinetics of MERS Coronavirus Infection
Oh, M., Park, W. B., Choe, P. G., Choi, S., Kim, J., Chae, J., Park, S. S., Kim, E.-C., Oh, H. S., Kim, E. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1511695 · Cited by 224
Self-citation
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Arabi, Y. M., Balkhy, H. H., Hajeer, A. H., Bouchama, A., Hayden, F. G., Al‐Omari, A., Al-Hameed, F. M., Taha, Y., Shindo, N., Whitehead, J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-1490-9 · Cited by 202
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Nsour, M. A., Alsanouri, T., Ali, S. S., Harcourt, J. L., Miao, C., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2210.160706 · Cited by 201

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 101–200 of 200

Dynamics of SARS-CoV-2 with waning immunity in the UK population
Crellen, T., Pi, L., Davis, E. L., Pollington, T. M., Lucas, T. C. D., Ayabina, D. V., Borlase, A., Toor, J., Prem, K., Medley, G. F., et al. (2021) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2020.0274 · Cited by 30
Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection
Castro, L. C. E., Gomes, A., Serrano, M., Pereira, A. H. G., Ribeiro, R., Napoleão, P., Domingues, I., Silva, C., Fanczal, J., Afonso, Â., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149619 · Cited by 30
SARS -CoV-2 T-cell immunity to variants of concern following vaccinationPreprint
Gallagher, K., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 32
Inter-species gene flow drives ongoing evolution of Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis
Xie, O., Morris, J. M., Hayes, A. J., Towers, R. J., Jespersen, M. G., Lees, J. A., Zakour, N. L. B., Berking, O., Baines, S. L., Carter, G. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46530-2 · Cited by 30
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Tarrés-Freixas, F., Ortiz, R., Rovirosa, C., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100523 · Cited by 29
Lack of serological evidence of Middle East respiratory syndrome coronavirus infection in virus exposed camel abattoir workers in Nigeria, 2016
So, R. T. Y., Perera, R. A. P. M., Oladipo, J. O., Chu, D. K. W., Kuranga, S. A., Chan, K. H., Lau, E. H. Y., Cheng, S. M. S., Poon, L. L. M., Webby, R. J., et al. (2018) · Eurosurveillance · doi:10.2807/1560-7917.es.2018.23.32.1800175 · Cited by 29
Self-citation
Risk Factors for MERS-CoV Seropositivity among Animal Market and Slaughterhouse Workers, Abu Dhabi, United Arab Emirates, 2014–2017
Khudhair, A., Killerby, M. E., Mulla, M. A., Elkheir, K. A., Ternanni, W., Bandar, Z. A., Weber, S., Khoury, M., Donnelly, G., Muhairi, S. A., et al. (2019) · Emerging infectious diseases · doi:10.3201/eid2505.181728 · Cited by 29
Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker
Kalpakçı, Y., Hacıbekiroğlu, T., Gülay, T. R. A. K., Karacaer, C., Demirci, T., Kocayiğit, H., Sunu, C., Varım, C., & Falay, M. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.12.1666 · Cited by 29
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection
Siracusano, G., Brombin, C., Pastori, C., Cugnata, F., Noviello, M., Tassi, E., Princi, D., Cantoni, D. M., Malnati, M., Maugeri, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772239 · Cited by 29
Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection
Choe, P. G., Kang, C. K., Kim, K., Yi, J., Kim, E. S., Park, S. W., Kim, N. J., Park, W. B., & Oh, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab339 · Cited by 27
Self-citation
Major bat‐borne zoonotic viral epidemics in Asia and Africa: A systematic review and meta‐analysis
Khan, S. A., Imtiaz, M. A., Islam, M. M., Tanzin, A. Z., Islam, A., & Hassan, M. M. (2022) · Veterinary Medicine and Science · doi:10.1002/vms3.835 · Cited by 27
Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018
Abbad, A., Perera, R. A. P. M., Anga, L., Faouzi, A., Minh, N. N. T., Malik, S. M. M. R., Iounes, N., Maaroufi, A., Kerkhove, M. D. V., Peiris, M. J. S., et al. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.48.1900244 · Cited by 26
Self-citation
SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020
Chirathaworn, C., Sripramote, M., Chalongviriyalert, P., Jirajariyavej, S., Kiatpanabhikul, P., Saiyarin, J., Soudon, C., Thienfaidee, O., Ayuthaya, T. P. N., Brukesawan, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236905 · Cited by 28
How to Understand Herd Immunity in the Context of COVID-19
Dong, M., He, F., & Deng, Y. (2020) · Viral Immunology · doi:10.1089/vim.2020.0195 · Cited by 30
A database of geopositioned Middle East Respiratory Syndrome Coronavirus occurrences
Ramshaw, R. E., Letourneau, I. D., Hong, A., Hon, J., Morgan, J. D., Osborne, J. C. P., Shirude, S., Kerkhove, M. D. V., Hay, S. I., & Pigott, D. M. (2019) · Scientific Data · doi:10.1038/s41597-019-0330-0 · Cited by 25
Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phasesPreprint
Yao, X., Liu, W. Y., Li, Z., Xiong, H., Su, Y., Li, T., Zhang, S., Zhang, X., Bi, Z., Deng, C.-X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-327912/v1 · Cited by 23
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21
Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans
Addetia, A., Stewart, C., Seo, A. J., Sprouse, K. R., Asiri, A. Y., Al-Mozaini, M., Memish, Z. A., Alshukairi, A. N., & Veesler, D. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114530 · Cited by 19
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 23
Certainty of success: three critical parameters in coronavirus vaccine development
Kaslow, D. C. (2020) · npj Vaccines · doi:10.1038/s41541-020-0193-6 · Cited by 22
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 26
COVID-19 reinfection: Linked Possibilities and future outlook
Krishna, E., Pathak, V. K., Prasad, R., Jose, H., & Mohan Kumar, M. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1672_20 · Cited by 20
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 22
Multihospital Outbreak of a Middle East Respiratory Syndrome Coronavirus Deletion Variant, Jordan: A Molecular, Serologic, and Epidemiologic Investigation
Payne, D. C., Biggs, H. M., Alabdallat, M., Alqasrawi, S., Lu, X., Abedi, G. R., Haddadin, A., Iblan, I., Alsanouri, T., Nsour, M. A., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy095 · Cited by 20
SARS-CoV-2—Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis
Grudlewska‐Buda, K., Wiktorczyk-Kapischke, N., Wałecka-Zacharska, E., Kwiecińska-Piróg, J., Buszko, K., Leis, K., Juszczuk, K., Gospodarek-Komkowska, E., & Skowron, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091962 · Cited by 27
Antibody Dynamics and Durability in Coronavirus Disease-19
Zuiani, A., & Wesemann, D. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.004 · Cited by 19
Molecular dynamics of Middle East Respiratory Syndrome Coronavirus (MERS CoV) fusion heptad repeat trimers
Kandeel, M. K., Al-Taher, A. Y., Li, H., Schwingenschlögl, U., & Al-Nazawi, M. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.05.020 · Cited by 20
Serologic Follow-up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts—Abu Dhabi, United Arab Emirates
Hosani, F. I. A., Kim, L., Khudhair, A., Pham, H., Mulla, M. A., Bandar, Z. A., Pradeep, K., Elkheir, K. A., Weber, S., Khoury, M., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy503 · Cited by 18
Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults
Jónsdóttir, H. R., Bielecki, M., Siegrist, D., Buehrer, T. W., Züst, R., & Deuel, J. (2021) · Viruses · doi:10.3390/v13020284 · Cited by 17
Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17
Genetic diversity and molecular epidemiology of Middle East Respiratory Syndrome Coronavirus in dromedaries in Ethiopia, 2017–2020
Zhou, Z., Ali, A., Walelign, E., Demissie, G., Masry, I. E., Abayneh, T., Getachew, B., Krishnan, P., Ng, D. Y. M., Gardner, E. G., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2164218 · Cited by 17
Self-citation
SARS-CoV-2-specific T cell memory is long-lasting in the majority of convalsecent COVID-19 individualsPreprint
Li, Z., Liu, J., Deng, H., Yang, X., Wang, H., Feng, X., Zelinskyy, G., Trilling, M., Sutter, K., Lu, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.15.383463 · Cited by 19
Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia
Alshukairi, A. N., Zhao, J., Al-Mozaini, M., Wang, Y., Dada, A. M., Baharoon, S. A., Alfaraj, S., Ahmed, W., Enani, M. A., Elzein, F. E., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2705.204056 · Cited by 17
Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Choe, P. G., Hong, J., Park, J., Chang, E., Kang, C. K., Kim, N. J., Lee, C. H., Park, W. B., & Oh, M. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac099 · Cited by 16
Self-citation
Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana
Mensah, B. A., Ndong, I. C., Quashie, P. K., Guichet, E., Abuaku, B. K., Effah-Baafi, Y., Tapela, K., Asiedu, K., Appiedu-Addo, S. N. A., Obbeng, L. B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25598-0 · Cited by 15
Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability
Ys, K., Aigerim, A., Park, U., Kim, Y., Park, H., Rhee, J.-Y., Choi, J., Park, W. B., Park, S., Kim, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1345 · Cited by 15
Self-citation
Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Dan, J. M., Antunes, R. D. S., Grifoni, A., Weiskopf, D., Crotty, S., & Sette, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac310 · Cited by 16
Middle East Respiratory Syndrome Coronavirus Infection Elicits Long-lasting Specific Antibody, T and B Cell Immune Responses in Recovered Individuals
Alhabbab, R. Y., Algaissi, A. A., Mahmoud, A. B., Alkayyal, A. A., Alamri, S. S., Alfaleh, M. A., Basabrain, M. A., Alsubki, R. A., Almarshad, I. S., Alhudaithi, A. M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac456 · Cited by 16
Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study
Cheon, S., Park, U., Park, H., Kim, Y., Yến, N. T. H., Aigerim, A., Rhee, J.-Y., Choi, J., Park, W. B., Park, S., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.009 · Cited by 14
Self-citation
Convalescent Plasma Therapy for Covid-19: State of the ArtPreprint
Focosi, D., Tang, J. W.-T., Anderson, A., & Tuccori, M. (2020) · Preprints.org · doi:10.20944/preprints202004.0097.v7 · Cited by 13
Applying Immune Instincts and Maternal Intelligence from Comparative Microbiology to COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00634-0 · Cited by 11
Adaptive immune responses to SARS-CoV-2
Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11
Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection
Abril, A. G., Alejandre, J., Mariscal, A., Alserawan, L., Rabella, N., Román, E. M., López-Contreras, J., Navarro, F., Serrano, E., Nomdedeu, J. F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59634-y · Cited by 10
An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus
Mackay, I. M., & Arden, K. E. (2017) · Viruses · doi:10.3390/v9120369 · Cited by 10
Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 DiseasePreprint
Tighe, P. J., Urbanowicz, R. A., Fairclough, L. C., McClure, C. P., Thomson, B. J., Gomez, N., Chappell, J. G., Tsoleridis, T., Loose, M., Carlile, M., et al. (2020) · medRxiv · doi:10.1101/2020.08.22.20176834 · Cited by 10
Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?
Kothari, A., Singh, V., Nath, U. K., Kumar, S., Rai, V., Kaushal, K., Omar, B. J., Pandey, A., & Jain, N. K. (2020) · Biology · doi:10.3390/biology9090243 · Cited by 9
Diagnostic performance of an automated chemiluminescence immunoassay for SARS-CoV-2 IgG and IgM antibodies detection: A real life experience
Villalta, D., Martelli, P., Moratto, A., Salgarolo, V., Ligato, E., Conte, M., Giacomello, R., Pellis, T., Rosa, R. D., Venturini, S., et al. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00227 · Cited by 9
Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?
Sinderewicz, E., Czelejewska, W., Jezierska‐Woźniak, K., Staszkiewicz‐Chodor, J., & Maksymowicz, W. (2020) · Pathogens · doi:10.3390/pathogens9090739 · Cited by 8
A Minimalist Strategy Towards Temporarily Defining Protection for COVID-19
Cimolai, N. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00533-4 · Cited by 8
Mucosal immunity in upper and lower respiratory tract to MERS-CoV
Shrwani, K. J., Mahallawi, W. H., Mohana, A., Algaissi, A. A., Dhayhi, N., Sharwani, N. J., Gadour, E., Aldossari, S. M., Asiri, H., Kameli, N., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1358885 · Cited by 8
Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
Türkkan, A., Saglik, I., Turan, C. A., Sahin, A., Akalin, H., Ener, B., Kara, A., Celebi, S., Sahin, E., & HACIMUSTAFAOĞLU, M. K. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02716-x · Cited by 8
Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study
Wang, Q., Yao, Y.-Z., Song, J.-S., Wang, Q., Xu, L., Bao, Z.-J., Mao, D.-W., Zhou, J., Zhang, Z., Wang, Y., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05549-8 · Cited by 8
Fatal SARS-CoV-2 reinfection in an immunosuppressed patient on hemodialysis
Rodríguez‐Espinosa, D., Broseta, J. J., Casals, Q., Piñeiro, G. J., Rodas, L. M., Vera, M., & Maduell, F. (2021) · Journal of Nephrology · doi:10.1007/s40620-021-01039-5 · Cited by 8
Local and introduced lineages drive MERS-CoV recombination in Egyptian camels
Gomaa, M. R., Edwards, K. M., Wang, R., Taweel, A. E., Moatasim, Y., Kutkat, O., Kamel, M. N., El-Nagar, H. A., Vijaykrishna, D., Ali, M. A., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00641-25 · Cited by 7
Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China
Bai, Z., Li, Q., Chen, Q., Niu, C., Wei, Y., Huang, H., Zhao, W., Chen, N., Yao, X., Zhang, Q., et al. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.09.001 · Cited by 8
Evaluation of humoral immune response in relation to COVID-19 severity over 1 year post-infection: critical cases higher humoral immune response than mild cases
Bang, M.-S., Kim, C., Cho, N., Seo, J.-W., Kim, D. Y., Yun, N. R., & Kim, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203803 · Cited by 7
Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population
Garde, J., Fernández-Murga, M. L., Giner‐Bosch, V., Domínguez-Márquez, V., Sánchez, J. G., Soler‐Cataluña, J. J., Chulía, F., Peris, B. H., Piera, N., & Llombart‐Cussac, A. (2020) · Cancers · doi:10.3390/cancers12123513 · Cited by 6
High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia
Taha, A. E., Alduraywish, A. A., Almaeen, A. H., El‐Metwally, T. H., Alayyaf, M., Mallick, A., & Abouelkheir, M. M. (2022) · Vaccines · doi:10.3390/vaccines11010026 · Cited by 7
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19
Barrios, M. H., Nicholson, S. R., Bull, R. A., Martinello, M., Rawlinson, W. D., Mina, M., Post, J. J., Hudson, B. J., Gilroy, N. M., Lloyd, A. R., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11081985 · Cited by 4
Potential pitfalls of routine SARS‐CoV‐2 serology for mass screening
Bélec, L., Péré, H., Bouassa, R. M., Veyer, D. L., & Jenabian, M.-A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26034 · Cited by 6
Convalescent Plasma Therapy for Covid-19: State of the ArtPreprint
Focosi, D., Tang, J. W.-T., Anderson, A. O., & Tuccori, M. (2020) · Preprints.org · doi:10.20944/preprints202004.0097.v5 · Cited by 6
Epidemiology and genomic features of MERS coronavirus in Africa: a systematic and meta-analysis review
Ogoti, B. M., Riitho, V., Wildemann, J., Mutono, N., Mureithi, M., Oyugi, J. O., Rodon, J., Corman, V. M., Drosten, C., Thumbi, S. M., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108456 · Cited by 5
Vacunas SARS CoV-2, estudios en fase III
Guelfenbein, C. I., Torres, J. P., & de Pablo, M. E. S. (2021) · Revista chilena de infectología · doi:10.4067/s0716-10182021000100088 · Cited by 8
SARS-CoV-2-specific T cell responses wane profoundly in convalescent individuals 10 months after primary infection
Li, Z., Xiang, T., Liang, B., Liu, J., Deng, H., Yang, X., Wang, H., Feng, X., Zelinskyy, G., Trilling, M., et al. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.06.011 · Cited by 5
Symptomatic MERS-CoV infection reduces the risk of future COVID-19 disease; a retrospective cohort study
El‐Saed, A., Othman, F. M., Baffoe-Bonnie, H., Almulhem, R., Matalqah, M., Alshammari, L., & Alshamrani, M. M. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08763-2 · Cited by 5
The immune response to the novel coronavirus infection
Fedorov, V. S., Ivanova, O. N., Karpenko, I. L., & Ivanov, A. V. (2021) · Journal of clinical practice · doi:10.17816/clinpract64677 · Cited by 7
Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus
Papaneophytou, C. P., Nicolaou, A., Pieri, M., Nicolaidou, V., Galatou, E., Sarigiannis, Y. M., Pantelidou, M., Panayi, P., Thoma, T., Stavraki, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269885 · Cited by 6
Serological Response to COVID-19 Vaccination in Saudi Arabia: A Comparative Study of IgG and Neutralising Antibodies Across Vaccine Platforms
AlEissa, M. M., Alsaieedi, A., Alduaiji, R., Almsned, F. M., Aldossary, Y. M., Saleh, N. M., AlQurashi, R. A., Hawsa, E. A., shaded, M. B., Alshehri, A. M., et al. (2025) · Vaccines · doi:10.3390/vaccines13101042 · Cited by 4
Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population
Roy, D. R., Rahman, M. M., Chaity, A. S., Reza, M. A., & Haque, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-18302-9 · Cited by 4
Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection
Wang, Y., Ji, W., Li, D., Sun, T., Zhu, P., Li, J., Zhang, L., Zhang, Y., Yang, H., Chen, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.083 · Cited by 4
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4
Human post‐infection serological response to the spike and nucleocapsid proteins of SARS‐CoV‐2
Xiao, C., Ling, S., Qiu, M., Deng, Z., Chen, L., Zhu, A., Chen, Y., Liu, Y., Lin, X., Lin, F., et al. (2020) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12798 · Cited by 3
Convalescent Blood Products in COVID-19: A Narrative Review
Long, K. C. V., Sayed, A., Karki, P., & Acharya, Y. (2020) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936120960646 · Cited by 4
Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal
Duro, M., Duro, I., Rebelo, I., Moreno, F., Pires, M., Jacinto, S., Pimentel, M., & Almeida, C. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02799-6 · Cited by 4
Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China
Gong, X., Cui, P., Wu, H., Pān, H., Teng, Z., Yuan, F., Mao, S., Kong, D., Han, R., Zhao, X., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07173-0 · Cited by 4
Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening
Srivastava, A. K., Gupta, A., Chauhan, D., Meena, R. C., Sugadev, R., Eslavath, M. R., Gupta, H., Karuna, K., Singh, S., Singh, Y., et al. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12113-8 · Cited by 4
Experimental re-infected cats do not transmit SARS-CoV-2Preprint
Gaudreault, N. N., Carossino, M., Morozov, I., Trujillo, J. D., Meekins, D. A., Madden, D. W., Cool, K. R., Artiaga, B. L., McDowell, C. D., Bold, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.18.427182 · Cited by 4
Genomic and patient epidemiology of Streptococcus dysgalactiae subspecies equisimilis in Houston, Texas
Pouga, L., Beres, S. B., Olsen, R. J., Long, S. W., Graviss, E. A., & Musser, J. M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03683-25 · Cited by 3
Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity
Guzmán-Martínez, O., Guardado, K., Cardoso, M. V., Trujillo-Rivera, A., Gómez-Ñañez, I., León, M. C. O., Espinosa, R., Ramos, C., Pérez‐Carreón, J. I., López-Guerrero, D. V., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179058 · Cited by 2
MERS-CoV seroconversion amongst Malaysian Hajj pilgrims returning from the Middle East, 2016–2018: results from the MERCURIAL multiyear prospective cohort study
Johari, J., Hontz, R. D., Pike, B. L., Husain, T., Rusli, N., Zain, R. M., Tiong, V., Lee, H. Y., Teoh, B., Sam, S., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2208678 · Cited by 3
(RE) currences in COVID-19
Shah, A. K., & Raul, M. U. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2178_20 · Cited by 3
Antibody Response to SARS-CoV-2: A Cohort Study in Qatar’s Primary Care Settings
Syed, M. A., Qotba, H. A. A., Nuaimi, A. S. A., Nasrallah, G. K., Thani, A. A. A., Zainel, A. A., Khudadad, H., Marji, T., Veettil, S. T., AlFehaidi, A. S., et al. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211050569 · Cited by 3
Convalescent Plasma Therapy for Covid-19: State of the ArtPreprint
Focosi, D., Tang, J. W.-T., Anderson, A., & Tuccori, M. (2020) · Preprints.org · doi:10.20944/preprints202004.0097.v4 · Cited by 3
Convalescent Plasma Therapy for Covid-19: State of the ArtPreprint
Focosi, D., Tang, J. W.-T., Anderson, A., & Tuccori, M. (2020) · Preprints.org · doi:10.20944/preprints202004.0097.v1 · Cited by 3
Middle East Respiratory Syndrome Coronavirus–Specific T-Cell Responses in Dromedary Camel Abattoir Workers in Nigeria Suggests Frequent Zoonotic Spillover
Mok, C. K. P., Zhu, A., Oladipo, J. O., Bai, H., Cheng, S. M. S., Kuranga, S. A., Lv, H., Zhao, J., & Peiris, M. J. S. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag095 · Cited by 2
Self-citation
ASEMPTOMATİK COVİD-19 OLGULARINDA BULAŞTIRICILIĞIN DEĞERLENDİRİLMESİ
PEKER, Ş., Ay, M. K., Girgin, Ş., Topuzoǧlu, A., & Save, D. (2022) · Eskişehir Türk Dünyası Uygulama ve Araştırma Merkezi Halk Sağlığı Dergisi · doi:10.35232/estudamhsd.942606 · Cited by 2
Features of the Formation of Seroprevalence to SARS-CoV2 in the Population of the Republic of Tatarstan during the Spread of COVID-19
Решетникова, И. Д., Agafonova, E. V., Khakimov, N. M., Tyurin, Y. A., Шайхразиева, Н. Д., & Ziatdinov, V. B. (2023) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2023-22-1-13-21 · Cited by 2
Nine-Month Trend of IgG Antibody Persistence and Associated Symptoms Post-SARS-CoV-2 Infection
Lugo‐Trampe, Á., López-Cifuentes, D., Pérez, P. M., Tafurt-Cardona, Y., Joo-Domínguez, A. D. J., Ríos-Ibarra, C. P., Espinoza-Ruiz, M., Chang-Rueda, C., Rodriguez-Sanchez, I. P., Martínez‐Fierro, M. L., et al. (2024) · Healthcare · doi:10.3390/healthcare12090948 · Cited by 2
The changing dynamics of neutralizing antibody response within 10 months of SARS‐CoV‐2 infections
Baştuğ, A., Bodur, H., Aydos, Ö., Filazi, N., Öksüz, E., & Özkul, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27544 · Cited by 2
Two-years antibody responses following SARS-CoV-2 infection in humans: A study protocol
Arguni, E., Dewi, F. S. T., Fachiroh, J., Paramita, D. K., Lestari, S. K., Wiratama, B. S., Susilaningrum, A. R., Kharisma, B., Meisyarah, Y. H., Sari, M. P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272690 · Cited by 2
Convalescent plasma for COVID-19: a reasonable option for the pandemic based on both scientific and practical point of views
Hardianti, M. S., Setiawan, S. A., Putera, D. D., Triyono, T., Thobari, J. A., & Kurnianda, J. (2020) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedscisi005203202011 · Cited by 2
A Comprehensive Review of Possible Immune Responses against Novel SARS-CoV-2 Coronavirus: Vaccines Strategies and Challenges
Shahriar, A., Mahmud, A. R., Ahmed, H. M., Rahman, N., & Khatun, M. C. (2021) · Austin Journal of Microbiology · doi:10.26420/austinjmicrobiol.2021.1028 · Cited by 2
Immunoinformatics Patterns and Characteristic of Epitope-Based Peptide Vaccine candidates against COVID-19Preprint
Mustafa, M. I., Abdelmoneim, A. H., & Makhawi, A. M. (2020) · doi:10.21467/preprints.164 · Cited by 2
SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian EpicentrePreprint
Baracco, A., Perotti, G. M., Filippin, A., Anesi, A., Beccarini, V., Raimondi, L., Galvani, S., Bosio, D., & Bergamaschi, E. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3650227 · Cited by 2
Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after the start of the COVID-19 pandemicPreprint
Castro, L. C. E., Gomes, A., Serrano, M., Pereira, A. H. G., Ribeiro, R., Napoleão, P., Domingues, I., Silva, C., Fanczal, J., Afonso, Â., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-603060/v1 · Cited by 2
Rational Vaccine Design for SARS-CoV-2 Virus—A Systematic ReviewPreprint
Ghosh, A., Pavlović, M. D., & Larrondo-Petrie, M. M. (2023) · Preprints.org · doi:10.20944/preprints202311.1607.v1 · Cited by 1
Human Challenge Studies with Coronaviruses Old and New
McKendry, R., Lemm, N., Papargyris, L., & Chiu, C. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_247 · Cited by 1
Persistent CD19+ B cell lymphopenia in critically ill COVID-19 patients 50 days after symptom onset
An, H. J., Li, T., Zhang, X., Hu, H., Zhang, C., Wang, Y., Jin, S., & Li, M. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1488607 · Cited by 1
Serological insights into MERS-CoV dynamics of antibody responses during acute and convalescent phases and their clinical relevance for diagnostics and immunity
Shrwani, K. J., Alharbi, A. M., Mahallawi, W. H., Asiri, A. Y., Assiri, A. M., Algaissi, A. A., Hashem, A. M., Alsafi, R., Jubran, M. A., Gadour, E., et al. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102854 · Cited by 1

Authors: Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., Lau, E. H. Y., Poon, L. L. M., Peiris, M., & Oh, M.-D.
Affiliations: Seoul National University (KR)
Corresponding author: Oh, Myoung-don
ORCID: Choe, Pyoeng Gyun
Perera, R.A.P.M.
Park, Wan Beom
Song, Kyoung-Ho
Bang, Ji Hwan
Kim, Eu Suk
Kim, Hong Bin
Park, Sang Won
Kim, Nam-Joong
Lau, Eric H.Y.
Poon, Leo L.M.
Peiris, Malik
Oh, Myoung-don
Venue: Emerging Infectious Diseases
Publisher: Centers for Disease Control and Prevention (CDC)
Published: 2017-07
Volume: 23
Issue: 7
Pages: 1079-1084
ISSN: 1080-6040 (ISSN-L)
1080-6059
DOI: 10.3201/eid2307.170310
PMC: PMC5512479
OpenAlex: W2612594162
Cited by: 227
References: 17
Citations by year: 2026: 7 · 2025: 3 · 2024: 8 · 2023: 12 · 2022: 21 · 2021: 60 · 2020: 91 · 2019: 13 · 2018: 7 · 2017: 5
FWCI: 24.63
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by
Locations: Emerging infectious diseases (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Funders: Seoul National University
Korea Health Industry Development Institute (HI15C3227)
Seoul National University Hospital
Hong Kong Government
National Institutes of Health
Health and Medical Research Fund
National Institute of Allergy and Infectious Diseases (HHSN272201400003C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
Keywords: MERS-CoV, neutralizing antibodies, spike protein antibodies, antibody kinetics, antibody waning, seroconversion, convalescent plasma
MeSH terms: Antibodies, Viral, Disease Outbreaks, Enzyme-Linked Immunosorbent Assay, Follow-Up Studies, Humans, Neutralization Tests, Seroepidemiologic Studies, Coronavirus Infections, History, 21st Century, Republic of Korea, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks